Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

The 43rd J.P. Morgan Healthcare Conference in San Francisco will see active participation by Korean pharmaceutical giants and ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

The conference has a significant impact, attracting other conventions to the city to coincide with J.P. Morgan's. Alex ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Less than two months after scoring what analysts deemed a "best-case" FDA approval for its cardiomyopathy drug Attruby, ...

J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' biggest wheelers ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Shares of Blueprint Medicines rose after the company said its flagship drug Ayvakit could bring in $2 billion in revenue by 2030. Shares were recently up 14%, to $99.70, midday Monday. The stock is up ...

Sonova Holding AG / Key word (s): Conference Sonova to present at the J.P. Morgan 2025 Healthcare Conference 13.01.2025 / 18:00 CET/CEST ...

Teva Pharmaceutical Industries Limited ( NYSE: TEVA) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 11:15 AM ET Richard Francis - President and CEO Eric Hughes - Head of R&D and Chief ...

Johnson & Johnson is starting the year off strong with a $14.6 billion acquisition of the biopharma firm Intra-Cellular Therapies — best known for its blockbuster drug Caplyta. The deal was announced ...